Evidence map›Paper›PMID 39529882›Full record

ArticleFrontiers in pharmacology2024

Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses.

Yi Luan, Desheng Xian, Changwen Zhao, Xin Qing, Hanlin He, Kaixuan Zheng, Wenjun Song, Taijiao Jiang, Wenjian Wang, Chaohui Duan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi LuanLaboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Desheng XianState Key Laboratory of Chemical Resource Engineering and Beijing Laboratory of Biomedical Materials, Key Laboratory of Biomedical Materials of Natural Macromolecules, Ministry of Education, University of Chemical Technology, Beijing, China.
Changwen ZhaoState Key Laboratory of Chemical Resource Engineering and Beijing Laboratory of Biomedical Materials, Key Laboratory of Biomedical Materials of Natural Macromolecules, Ministry of Education, University of Chemical Technology, Beijing, China.
Xin QingWestchina Hospital, Sichuan University, Chengdu, China.
Hanlin HeLaboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Kaixuan ZhengLaboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Wenjun SongLaboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Taijiao JiangLaboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.
Wenjian WangDepartment of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Chaohui DuanLaboratory Testing and Diagnosis Technology Department of Guangzhou National Laboratory, Clinical Laboratory of Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer, categorized into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), remains a significant global health challenge. The development of drug resistance and the heterogeneity of the disease necessitate the identification of novel therapeutic targets to improve patient outcomes. Methods: We conducted a genome-wide Mendelian randomization (MR) and colocalization analysis using a comprehensive dataset of 4,302 druggable genes and cis-expressed quantitative trait loci (cis-eQTLs) from 31,884 blood samples. The study integrated genomic analysis with eQTL data to identify key genes associated with lung cancer risk. Results: The analysis revealed five actionable therapeutic targets for NSCLC, including LTB4R, LTBP4, MPI, PSMA4, and TCN2. Notably, PSMA4 demonstrated a strong association with both NSCLC and SCLC risks, with odds ratios of 3.168 and 3.183, respectively. Colocalization analysis indicated a shared genetic etiology between these gene expressions and lung cancer risk. Conclusion: Our findings contribute to precision medicine by identifying druggable targets that may be exploited for subtype-specific lung cancer therapies.

Indexed as

colocalization analysesdrug targetGWASlung cancerMendelian randomization

Identifiers

PMID39529882
PMCPMC11551539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.